Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 17, 2006, Pages 4483-4487

  Navidpour, Latifeh ^a   Amini, Mohsen ^a   Shafaroodi, Hamed ^b   Abdi, Khosrou ^a   Ghahremani, Mohammad H ^a   Dehpour, Ahmad Reza ^c   Shafiee, Abbas ^a  

^a Tehran University of Medical Science   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Celecoxib; Cyclooxygenase (COX 2) inhibitors; Parecoxib; Parenteral; Tetrazole

Indexed keywords

4 (4 METHYLPHENYL) 1 [4 (5 TETRAZOLYL)PHENYL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE; 4 [4 (5 TETRAZOLYL)PHENYL] 3 PHENYL 2(5H) FURANONE; ARGININE; CARRAGEENAN; CELECOXIB; CELECOXIB DERIVATIVE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ROFECOXIB; ROFECOXIB DERIVATIVE; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; WATER;

ACIDITY; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; ELECTRICITY; HYDROGEN BOND; IC 50; MOLECULAR MODEL; NONHUMAN; PAW EDEMA; PHARMACOPHORE; RAT; STOMACH MUCOSA; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; LACTONES; MOLECULAR STRUCTURE; PYRAZOLES; RATS; SOLUBILITY; STOMACH; SULFONAMIDES; SULFONES; WATER;

EID: 33746233248     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.06.032     Document Type: Article

References (32)

1. DeWitt D.L. Mol. Pharmacol. 55 (1999) 625
2. Chung S., Lim K.M., and Shin S.S. Expert Opin. Ther. Patents 15 (2005) 9
3. Talley J.J. In: King F.D. (Ed). Progress in Medicinal Chemistry Vol. 36 (1999), Elsevier, Amsterdam 201
4. Almansa C., Bartolí J., Belloc J., Cavalcanti F.L., Ferrando R., Gómez L.A., Ramis I., Carceller E., Merlos M., and García-Rafanell J. J. Med. Chem. 47 (2004) 5579
5. Kimmel S.E., Berlin J.A., Kinman J.L., Hennessy S., Feldman H., Carson J.L., and Storm B.L. Pharmacoepidemiol. Drug Saf. 11 (2002) 113
6. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., and Simmons D.L. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2692
7. Jujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., and Herschman H.R. J. Biol. Chem. 266 (1991) 12866
8. Vane J.R. Nature 367 (1994) 215
9. Masferrer J.L., Zweifel B.S., and Manning P.T. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3228
10. Prasit P., Wang Z., Brideau C., Chan C.-C., Charleson S., Cromlish W., Ethier D., Evans J.F., Ford-Hutchinson A.W., Gauthier J.Y., Gordon R., Guay J., Gresser M., Kargman S., Kennedy B., Leblanc Y., Léger S., Mancini J., ÓNeill G.P., Quellet M., Percival M.D., Perrier H., Riendeau D., Rodger Y., Tagari P., Thérien M., Vickers P., Wong E., Xu L.-J., Young R.N., and Zamboni R. Bioorg. Med. Chem. Lett. 9 (1999) 1773
11. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., and Isakson P.C. J. Med. Chem. 40 (1997) 1347
12. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Massferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., and Seibert K. J. Med. Chem. 43 (2000) 775
13. Riendeau D., Percival M.D., Brideau C., Charleson S., Dubé D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., quelled M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford-Hutchinson A.W., Young R.N., and Chan C.C. J. Pharmacol. Exp. Ther. 296 (2001) 558
14. Dogné J.M., Supuran C.T., and Pratico D.J. J. Med. Chem. 48 (2005) 2251
15. Grosser T., Fries S., and FitzGerald G.A. J. Clin. Invest. 116 (2006) 4
16. Talley J.J., Bertenshaw S.R., Brown D.L., Carter J.S., Graneto M.J., Kellogg M.S., Koboldt C.M., Yuan J., Zhang Y.Y., and Seibert K. J. Med. Chem. 43 (2000) 1661
17. Habeeb A.G., Praveen Rao P.N., and Knaus E.E. J. Med. Chem. 44 (2001) 3039
18. Navidpour L., Shafaroodi H., Abdi K., Amini M., Ghahremani M.H., Dehpour A.R., and Shafiee A. Bioorg. Med. Chem. 14 (2006) 2507
19. Therin M., Gauthier J.Y., Leblanc Y., Leger S., Perrier H., Prasit P., and Wang Z. Synthesis 12 (2001) 1778
20. Shie J.-J., and Fang J.-M. J. Org. Chem. 68 (2003) 1158
21. 6: C, 58.38; H, 3.54; N, 22.69. Found: C, 58.29; H, 3.69; N, 22.82.
22. Docking studies were performed using MOE software version 2003.02 (CCG Inc.). The coordinates of the X-ray crystal structure of the selective COX-2 inhibitor SC-558 bound to the murine COX-2 enzyme were obtained from the RCSB Protein Data Bank (1cx2). The ligand molecules were constructed using the Builder module and were energy optimized. The purpose of docking is to search for favorable binding configuration between the small flexible ligands and the rigid protein. Protein residues with atoms greater than 7.5 Å from docking box were removed for efficiency. Searching is conducted within a specified 3D docking box using simulated annealing based on Monte Carlo method and MMFF94 molecular mechanics force fields for 8000 iterations.
23. MOE. Chemical Computing Group Inc., Montreal, Que., Canada, 2003.02, see http://www.chemcomp.com.
24. 23 The reaction mixture (200 μL) contained 0.5 μM heme, 0.05 mM TMPD, 0.1 mM AA, and 36 units of COX-2 enzyme (57 units for COX-1, Sigma Co.) in 0.1 M Tris/HCl (pH 8.1). The oxidation of substrate was measured at 25 °C by monitoring the increase of absorbance at 630 nm. The absorption due to the spontaneous oxidation of TMPD was subtracted from the initial rate of oxidation observed in the presence of AA. The inhibition of the studied compounds (9 and 13) was determined after preincubation for 5 min with the enzyme in the presence of heme, and the reaction was started by adding AA and TMPD. The mixture was incubated for further 5 min and the absorbance was measured on a strip reader. For synthesized compounds (9 and 13) 10 μL of scalar dilutions of the inhibitors in DMSO was added. Celecoxib, a potent and selective COX-2 inhibitor, has been used as a reference drug.
25. Kulmacz R.J., and Lands W.E.M. Prostaglandins 25 (1983) 531
26. Kulmacz R.J. Prostoglandins 34 (1987) 225
27. Rouzer C.A., and Marnett L.J. Chem. Rev. 103 (2003) 2239
28. Kontogiorgis C.A., and Hadjipavlou-Litina D.J. J. Med. Chem. 48 (2005) 6400
29. 2O (5 mL). The percentage were calculated by the following equation: anti-inflammatory activity (%) = (1 - D/C) × 100, where D represents the difference in paw volume before and after drug was administered to the rats, and C stands for the difference of volume in the control groups.
30. Suleyman H., Demirezer L.O., Kuruuzum A., Banoglu Z.N., Gocer F., Ozbakir G., and Gepgiremen A. J. Ethnopharmacol. 65 (1999) 141
31. Padi S.S.V., Jain N.K., Singh S., and Kulkarini S.K. Eur. J. Pharmacol. 491 (2004) 69
32. Equilibrium solubilities were obtained by adding solid compounds directly to an aqueous medium, followed by adding 1 equiv of KOH and stirring at room temperature for 24 h. Suspensions then were filtered and the remaining concentration in the solution was measured spectrophotometrically at 306 and 256 nm wavelengths for compounds 9 and 13, respectively.